Incyclix Bio

United States - Durham, North Carolina

• 26/08/2025
• Series B
• $11,250,000

Incyclix Bio, LLC is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor nearing clinical stage. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development.

Related People

Patrick RobertsFounder

United States - Chapel Hill, North Carolina

Scientist/Drug Developer: Over 10 years of pharmaceutical experience with expertise in oncology and drug development. Breadth in drug development ranging from discovery through clinical development.

Inventor: As inventor/coinventor, helped to build robust IP portfolio at G1 Therapeutics, including patents supporting 2 clinical stage compounds.

Entrepreneur: Worked to build G1 Therapeutics, both scientifically and operationally, from a UNC Chapel Hill incubated start-up to a public company. Presented company to potential investors and supported due diligence. Raised operating capital from grants, loans and multiple rounds of venture capital prior to IPO.

Leader: As the Trilaciclib Project Leader, led nonclinical and clinical cross-functional teams to deliver trilaciclib from discovery through Phase 2 clinical testing. As the head of the translational medicine team, led research efforts to support development of three clinical stage compounds, as well as novel pipeline programs.

LinkedIn https://www.linkedin.com/in/pjroberts77/